Cathie Wood Is Selling. Analysts Are Buying. Who’s Right on Strata Critical Medical?

TLDR

• ARK Invest sold 182,767 shares of Strata Critical Medical across two ETFs on April 13, 2026, worth around $738,378
• The selling is part of a multi-day pattern, with ARK also offloading over 75,000 shares on April 10
• Strata Critical Medical is a healthcare logistics company focused on organ transplant transport in the U.S.
• Two Wall Street analysts recently initiated coverage with Buy ratings and price targets of $8
• The average analyst price target of $9.08 implies over 120% upside from the current price of around $4.12

Cathie Wood’s ARK Invest has been steadily cutting its position in Strata Critical Medical over the past week. On April 13, 2026, ARK sold 182,767 shares of the company through two of its ETFs — the ARK Autonomous Technology & Robotics ETF and the ARK Space Exploration & Innovation ETF. The combined sale was worth approximately $738,378.

Strata Critical Medical, Inc., SRTA

This was not a one-off move. ARK also sold more than 75,000 shares of the stock on April 10, and the firm has recorded sales on multiple days in the same period. The pattern points to a deliberate decision to reduce exposure to the company.

Strata Critical Medical is a small-cap healthcare logistics company. It runs one of the largest air transport and surgical service networks for organ transplant hospitals in the United States. The company calls itself the only end-to-end platform in organ transplant logistics.

The stock is currently trading around $4.12 per share. It closed 2% higher on April 13 and has gained 51% over the past year, putting it in penny stock territory.

Analysts Still Bullish Despite ARK’s Selling

Despite the ARK selloff, two Wall Street analysts recently started coverage of the stock with positive ratings.

B. Riley analyst Yuan Zhi initiated coverage with a Buy rating and an $8 price target. Zhi said the company holds a strong position in the U.S. organ transplant market and is the only platform offering end-to-end logistics in this space.

Craig-Hallum analyst Bill Bonello also initiated with a Buy rating and an $8 price target. Bonello said the company has made major changes over the past year, but its growth outlook is not yet reflected in the current stock price.

Both analysts believe investor confidence could grow as the company’s financials become clearer.

What the Numbers Show

On TipRanks, Strata Critical Medical holds a Strong Buy consensus rating based on three unanimous Buy recommendations.

The average analyst price target sits at $9.08. That implies more than 120% upside from the current price of around $4.12.

Bonello added that current analyst estimates for the company may actually be conservative, suggesting there could be more room to grow than the numbers reflect.

ARK has not publicly stated a reason for the ongoing sales, and no new buys were reported on April 13.

The stock closed at $4.12 on April 13, 2026, with three Buy-rated analysts and an average price target of $9.08 on record.

The post Cathie Wood Is Selling. Analysts Are Buying. Who’s Right on Strata Critical Medical? appeared first on CoinCentral.